肽受体放射性核素治疗改善胰腺神经内分泌肿瘤患者生活质量:基于EORTC QLQ-C30的评估
本研究纳入68例胰腺神经内分泌肿瘤(P-NET)患者接受肽受体放射性核素治疗(PRRT),采用EORTC QLQ-C30问卷在基线和每3个月评估生活质量。主要分析(N=53)显示,第四个治疗周期后整体健康状况(p=0.008)和社会功能(p=0.049)较基线显著改善,疲乏(p=0.029)和食欲丧失(p=0.015)也显著改善。结论认为PRRT是P-NET的有效治疗,可提高整体健康并减轻躯体不适。
要点
- PRRT后整体健康状况(p=0.008)和社会功能(p=0.049)较基线显著改善。
- 第四个周期后疲乏(p=0.029)和食欲丧失(p=0.015)显著改善。
- 亚分析显示多个周期后整体健康、情绪功能和社会功能均有显著改善。
核心结论
- PRRT是胰腺神经内分泌肿瘤的有效治疗,可提高整体健康并减轻躯体不适,从而改善患者生活质量。
研究设计与样本
- 本研究纳入68例胰腺神经内分泌肿瘤患者(31例女性,平均年龄61.4岁),接受PRRT治疗。
- 肿瘤分级:1级12例,2级40例,3级8例,分级不可用8例。
- 治疗前ECOG评分:0分39例,1分26例,2分3例。
- 采用EORTC QLQ-C30标准化问卷在基线和每个治疗周期后每3个月评估生活质量,直至12个月。
- 主要分析比较基线与第四个治疗周期后(N=53)的生活质量。
主要发现
- 每位患者最多接受四个周期PRRT,中位累积给药活度为28.2 GBq。
- 主要分析显示,研究结束时整体健康状况较基线显著改善(p=0.008),社会功能显著改善(p=0.049)。
- 最后一个PRRT周期后,疲乏(p=0.029)和食欲丧失(p=0.015)较基线显著改善。
- 亚分析显示,整体健康状况在第一、第二和第三个治疗周期后3个月均显著改善(分别为p=0.048、p=0.002、p<0.001)。
- 情绪功能在第一至第三个周期后3个月均显著改善(分别为p=0.003、p=0.049、p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors. The aim of this study was to evaluate changes in quality of life (QoL) of patients with P-NET following PRRT. METHODS: Sixty-eight patients with P-NET (31 female, mean age 61.4 y) underwent PRRT: 12 with NET of grade 1, 40 of grade 2, 8 of grade 3 (grade non-available n = 8). Prior to treatment, 39 patients showed ECOG 0, 26 patients ECOG 1, and three patients ECOG 2. Clinical assessment included evaluation of QoL and symptom changes using a standardized questionnaire (EORTC QLQ-C30) and was performed at baseline and every three months following each therapy cycle up to 12 months. Primary analysis compared QoL at baseline and after the fourth treatment cycle (N = 53). RESULTS: Up to four treatment cycles PRRT were performed for each patient. The median cumulative administered activity was 28.2 GBq. Primary analysis revealed that compared to baseline QoL was significantly improved revealing increased global health status (p = 0.008) and social functioning (p = 0.049) at the end of the study. Furthermore, fatigue and appetite loss showed a significant improvement after the last PRRT cycle (fatigue: p = 0.029, appetite loss p = 0.015). Sub-analyses showed that QoL was improved revealing increased global health status (3 months after first, second, and third treatment cycle p = 0.048, p = 0.002, and p < 0.001, respectively), emotional functioning (3 months after first-third cycle p = 0.003, p = 0.049, and p = 0.001, respectively) and social functioning (3 months after the first and second p < 0.001, and after the third cycle p = 0.015, respectively). Furthermore, some symptoms were significantly alleviated compared with baseline: fatigue (after first-third cycle p = 0.026, p = 0.050, and p = 0.008, respectively), nausea and vomiting (after first and second cycle p = 0.006 and p = 0.001, respectively), dyspnea (after third cycle p = 0.025), appetite loss (after first-third cycle p = 0.010, p = 0.001, and p = 0.009, respectively), constipation (after first-third cycle p = 0.050, p = 0.003, and p = 0.060, respectively). CONCLUSION: PRRT is an effective treatment of P-NET improving QoL of patients in terms of increasing global health and mitigation of physical complaints.
引用
- Marinova M, Mücke M, Mahlberg L, et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging. 2017. PMID: 28864881. doi:10.1007/s00259-017-3816-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。